Perspectives of improvement of the diagnosis of prostate cancer based on analysis of PCA3 gene expression

Toropovsky, A.N. Toropovsky; Никитин, А Г; Pavlova, O. N.; Viktorov, D. A.

doi:10.18565/urology.2019.2.82-86

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…В контексте проблемы раннего выявления рака простаты трудно переоценить значимость ПСА, но его определение имеет ограниченные возможности в качестве диагностического маркера. В случае неоднократного повышения уровня ПСА пациенту в итоге будет выполнена биопсия, при этом, как известно, высокие значения ПСА иногда не соответствуют наличию РПЖ [4]. То есть ПСА -это низкоспецифичный маркер, его положительная предсказательная ценность при раке простаты составляет не более 25 %, что приводит к выполнению необязательных биопсий.…”

unclassified

Current biomarkers of prostate cancer

Aboian

FEDOTOVA

Шевченко

et al. 2021

Issled. prakt. med. (Print)

View full text Add to dashboard Cite

Prostate cancer is one of the most common malignancies in men. Early detection of prostate cancer is largely determined by the widely used prostate specific antigen (PSA) blood test. However, as a diagnostic and prognostic test of prostate cancer, PSA has limited specificity, sensitivity and leads to hyper or underdiagnosis, which, in turn, can lead to excessive treatment. There fore, it is very important to develop diagnostic markers that can be used to determine prostate cancer at an early stage of development, assess the possible progression of the disease and prescribe optimal therapy. Significant progress has been made in the discovery of biomarkers for prostate cancer. For example, biomarkers such as %-free PSA, Prostate Health Index (PHI) or 4K score can be used to increase specificity and reduce the number of unnecessary biopsies, while the PCA3 test can be used to reduce the number of repeated biopsies in men with previously negative biopsy. To determine aggressiveness and predict the outcome of the disease, tissue multigenic tests can be used, such as: T2-ERG, ExoDx, SelectMDx and ConfirmMDx, Prolaris, Oncoytype DX, Decipher. The development of such diagnostic tests opens up new opportunities for improving the diagnosis of prostate cancer, prognosis and decision-making on the appointment of therapy. And with the increase in their availability, finally, the possibility of an individual approach to the appointment of treatment for men with prostate cancer appears on the horizon. This review paper presents the data on the most advanced diagnostic biomarkers of prostate cancer.

show abstract

unclassified

Current biomarkers of prostate cancer

Aboian

FEDOTOVA

Шевченко

et al. 2021

Issled. prakt. med. (Print)

View full text Add to dashboard Cite

show abstract

Modern prostate cancer biomarkers. Prospects for EN2 in the prostate cancer diagnosis

Тарабаева¹,

Жубантурлиева²,

Охас³

2020

Onkourologiâ

View full text Add to dashboard Cite

Prostate cancer is one of the most common forms of malignant neoplasms in men. In this regard, it is relevant to search for diagnostic markers that allow the creation of inexpensive, effective tests for early diagnosis of the disease, predicting the risk of relapse and assessing the effectiveness of the therapy. Existing invasive methods for diagnosing prostate cancer present some difficulties for patients. This article discusses the diagnostic capabilities of tissue biomarkers of prostate cancer obtained by non-invasive methods.

show abstract

Perspectives of improvement of the diagnosis of prostate cancer based on analysis of PCA3 gene expression

Cited by 2 publications

References 0 publications

Current biomarkers of prostate cancer

Current biomarkers of prostate cancer

Modern prostate cancer biomarkers. Prospects for EN2 in the prostate cancer diagnosis

Contact Info

Product

Resources

About